Multimodality brain tumor imaging: MR imaging, PET, and PET/MR imaging

Journal of Nuclear Medicine

Volumn 56, Issue 10, 2015, Pages 1554-1561

  Fink, James R ^a   Muzi, Mark ^a   Peck, Melinda ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; AMINO ACID; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN TUMOR; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; NEUROANATOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCINTIGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR DIAGNOSIS; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; MULTIMODAL IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84943170441     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.113.131516     Document Type: Article

References (80)

1. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
2. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
3. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583-593.
4. Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012;70: 234-243.
5. Kwock L, Smith JK, Castillo M, et al. Clinical applications of proton MR spectroscopy in oncology. Technol Cancer Res Treat. 2002;1:17-28.
6. 1H magnetic resonance spectroscopy. Magn Reson Med. 2003;49:223-232.
7. 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR. 2006;27:560-572.
8. Pal D, Bhattacharyya A, Husain M, Prasad KN, Pandey CM, Gupta RK. In vivo proton MR spectroscopy evaluation of pyogenic brain abscesses: a report of 194 cases. AJNR. 2010;31:360-366.
9. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2∗-weighted MR imaging. Radiology. 1999;211:791-798.
10. Roberts HC, Roberts TP, Bollen AW, Ley S, Brasch RC, Dillon WP. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: a study in human brain tumors. Acad Radiol. 2001;8:384-391.
11. 15O positron emission tomography. Eur J Radiol. 2009;70:465-474.
12. 1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232.
13. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR. 2004;25:214-221.
14. Heiland S, Benner T, Debus J, Rempp K, Reith W, Sartor K. Simultaneous assessment of cerebral hemodynamics and contrast agent uptake in lesions with disrupted blood-brain-barrier. Magn Reson Imaging. 1999;17:21-27.
15. Gahramanov S, Muldoon LL, Varallyay CG, et al. Pseudoprogression of glioblas-toma after chemo-and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology. 2013;266:842-852.
16. Rosen BR, Belliveau JW, Aronen HJ, et al. Susceptibility contrast imaging of cerebral blood volume: human experience. Magn Reson Med. 1991;22:293-299.
17. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. 2008;249:601-613.
18. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490-498.
19. Jain R, Poisson L, Narang J, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology. 2013;267:212-220.
20. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401-407.
21. Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR. 2001;22:1081-1088.
22. Chang SC, Lai PH, Chen WL, et al. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. Clin Imaging. 2002;26:227-236.
23. Beauchamp NJ Jr., Ulug AM, Passe TJ, van Zijl PC. MR diffusion imaging in stroke: review and controversies. Radiographics. 1998;18:1269-1283.
24. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111: 209-219.
25. Mori S, van Zijl PC. Fiber tracking: principles and strategies-a technical review. NMR Biomed. 2002;15:468-480.
26. Smits M, Vernooij MW, Wielopolski PA, Vincent AJ, Houston GC, van der Lugt A. Incorporating functional MR imaging into diffusion tensor tractography in the preoperative assessment of the corticospinal tract in patients with brain tumors. AJNR. 2007;28:1354-1361.
27. White ML, Zhang Y, Yu F, Jaffar Kazmi SA. Diffusion tensor MR imaging of cerebral gliomas: evaluating fractional anisotropy characteristics. AJNR. 2011;32: 374-381.
28. Byrnes TJ, Barrick TR, Bell BA, Clark CA. Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo. NMR Biomed. 2011;24:54-60.
29. Price SJ, Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR. 2006;27:1969-1974.
30. Bagadia A, Purandare H, Misra BK, Gupta S. Application of magnetic resonance tractography in the perioperative planning of patients with eloquent region intra-axial brain lesions. J Clin Neurosci. 2011;18:633-639.
31. Romano A, D'Andrea G, Minniti G, et al. Pre-surgical planning and MR-tractography utility in brain tumour resection. Eur Radiol. 2009;19:2798-2808.
32. Bizzi A, Blasi V, Falini A, et al. Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. Radiology. 2008;248:579-589.
33. Ulmer JL, Salvan CV, Mueller WM, et al. The role of diffusion tensor imaging in establishing the proximity of tumor borders to functional brain systems: implications for preoperative risk assessments and postoperative outcomes. Technol Cancer Res Treat. 2004;3:567-576.
34. Pillai JJ. The evolution of clinical functional imaging during the past 2 decades and its current impact on neurosurgical planning. AJNR. 2010;31:219-225.
35. Holodny AI, Schulder M, Liu WC, Wolko J, Maldjian JA, Kalnin AJ. The effect of brain tumors on BOLD functional MR imaging activation in the adjacent motor cortex: implications for image-guided neurosurgery. AJNR. 2000;21: 1415-1422.
36. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncol. 2001;3:193-200.
37. Majós C, Bruna J, Julia-Sape M, et al. Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas. AJNR. 2011;32: 74-80.
38. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453-461.
39. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22:633-638.
40. Young RJ, Gupta A, Shah AD, et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology. 2011;76:1918-1924.
41. Galbán CJ, Chenevert TL, Meyer CR, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009;15:572-576.
42. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26: 3387-3394.
43. Galbán CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res. 2011;17:4751-4760.
44. Fink JR, Carr RB, Matsusue E, et al. Comparison of 3 Tesla proton MR spec-troscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging. 2012;35:56-63.
45. Di Costanzo A, Scarabino T, Trojsi F, et al. Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach. Radiol Med (Torino). 2014;119:616-624.
46. Rock JP, Scarpace L, Hearshen D, et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopa-thology with special attention to radiation necrosis. Neurosurgery. 2004;54: 1111-1117.
47. Smith JS, Cha S, Mayo MC, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg. 2005;103:428-438.
48. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol. 2005;32:663-671.
49. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.
50. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653-1659.
51. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.
52. Valk PE, Dillon WP. Radiation injury of the brain. AJNR. 1991;12:45-62.
53. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217:377-384.
54. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR. 1998;19:407-413.
55. Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR. 2013;34:944-950, S941-S911.
56. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
57. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
58. 18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612-1621.
59. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 39-fluoro-39-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008;14:2049-2055.
60. 18F-FDG. J Nucl Med. 2005;46: 945-952.
61. 18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol. 2009;11:343-355.
62. 18F]-FLT. Q J Nucl Med Mol Imaging. 2015;59:95-104.
63. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276.
64. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38-47.
65. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398-405.
66. Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med. 1987;28:68-75.
67. 15O-H2O. J Nucl Med. 2004;45:1851-1859.
68. 18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623-2630.
69. 18F-fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant glio-mas. Eur J Nucl Med Mol Imaging. 2012;39:760-770.
70. Pirotte BJ, Levivier M, Goldman S, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009;64:471-481.
71. 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73:479-485.
72. 18F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779-787.
73. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904-911.
74. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248:1028-1035.
75. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198-1205.
76. Bailey DL, Antoch G, Bartenstein P, et al. Combined PET/MR: The real work has just started-summary report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tubingen, Germany. Mol Imaging Biol. 2015;17:297-312.
77. Weber MA, Henze M, Tuttenberg J, et al. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol. 2010;45: 755-768.
78. 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. J Neurol Neuro-surg Psychiatry. 2011;82:512-520.
79. Bisdas S, Ritz R, Bender B, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Invest Radiol. 2013;48:295-301.
80. 18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci. 2010;17:50-53.